介酶体流体细胞:新一代治疗炎症性肠病的新一代治疗方法
Shulin Wei1,2, Mingxing Li1,2, Qin Wang1,2
1Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, 646100, People's Republic of China.
Journal of inflammation research
|May 27, 2024
概括
介酶体 stromal 细胞 (MSCs) 通过调节免疫力和修复肠道来治疗炎症性肠病 (IBD) 是有前途的. 临床试验证实了它们的安全性和有效性,尽管广泛使用仍然存在挑战.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 再生医学是一种再生医学.
背景情况:
- 炎症性肠病 (IBD) 是一种慢性,无法治愈的胃肠道疾病,复发率高.
- 介酶体 stromal 细胞 (MSCs) 具有自我更新和免疫调节性质,证明了IBD的治疗潜力.
- 目前的IBD治疗方法有限,需要新的治疗策略.
研究的目的:
- 综合审查MSC在IBD治疗中的治疗效果和机制.
- 总结最新的临床试验进展和基于MSC的IBD治疗方法的结果.
- 讨论MSC与传统IBD药物的优势,并确定未来的研究方向.
主要方法:
- 临床前研究研究了MSCs的膜作用,细胞与细胞接触,线粒体转移,本源,微生物组调节和上皮细胞修复.
- 对IBD自身/异种MSC输血 (骨髓,带,脂肪) 和细胞外囊泡的临床试验数据的分析.
- 审查关于MSC机制,临床应用,IBD管理中的挑战和未来前景的现有文献.
主要成果:
- 在IBD中,MSC通过免疫调节,肠道屏障恢复,微生物组调节和上皮修复发挥治疗作用.
- 临床试验证实了各种MSC类型和衍生细胞外囊泡在治疗IBD中的安全性和有效性.
- 与传统疗法相比,MSC治疗提供了潜在的优势,包括减少副作用和提高疗效.
结论:
- MSCs代表了IBD的有前途的基于细胞的治疗方法,提供了多方面的治疗机制.
- 需要进一步的研究来解决临床管理方面的挑战,包括细胞采购,剂量,管理和潜在的不良反应.
- 优化MSC应用具有促进IBD治疗和改善患者治疗结果的巨大潜力.
相关概念视频
Mesenchymal Stem Cells
4.7K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.7K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131
Drugs for Treatment of Ulcerative Colitis in IBD
135
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
135
Inflammatory Bowel Disease IV: Pharmacological Management
126
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
126


